Brief: Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs
04/04/2025 01:15
April 4 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST CELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFS CELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFS ALLOGENEIC CELLULAR PRODUCTS, INCLUDING RYONCIL AND REVASCOR, WILL NOT BE SUBJECT TO TARIFFS Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M